Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series

Respir Investig. 2020 Nov;58(6):510-512. doi: 10.1016/j.resinv.2020.09.006. Epub 2020 Oct 7.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • COVID-19 Drug Treatment*
  • Cytokine Release Syndrome / drug therapy*
  • Cytokine Release Syndrome / virology
  • Humans
  • Interleukin-6 / antagonists & inhibitors*
  • Japan / epidemiology
  • Respiratory Distress Syndrome* / drug therapy
  • Respiratory Distress Syndrome* / virology

Substances

  • Antibodies, Monoclonal, Humanized
  • Interleukin-6
  • tocilizumab